Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
Disrupting Stagnant Women’s Reproductive Health Ecosystem with Safer More Accessible Options with Kathy Lee-Sepsick Femasys